About ReproCELL
ReproCELL is a company based in Osaka (Japan) founded in 2003. The company has 99 employees as of March 31, 2024. ReproCELL has completed 4 acquisitions, including BioServe Biotechnologies, Biopta and Reinnervate. ReproCELL operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Osaka, Japan
- Employees 99 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Reprocell Inc.
-
Annual Revenue
$19.94 M (USD)22.74as on Mar 31, 2025
-
Net Profit
$690.95 K (USD)0as on Mar 31, 2025
-
EBITDA
-$533.35 K (USD)78.58as on Mar 31, 2025
-
Latest Funding Round
$292.58 K (USD), Grant
Oct 25, 2019
-
Investors
Maryland Stem Cell Research Fund
& 1 more
-
Employee Count
99
as on Mar 31, 2024
-
Investments & Acquisitions
BioServe Biotechnologies
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ReproCELL
ReproCELL is a publicly listed company on the TSE with ticker symbol 4978 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of ReproCELL
Unlock access to complete
Unlock access to complete
Funding Insights of ReproCELL
Investors in ReproCELL
ReproCELL has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Maryland Stem Cell Research Fund and SBI Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stem cell research startups in healthcare are funded and accelerated.
|
Locked | Locked | Locked | |
|
Venture capital funds are managed to support unlisted companies' growth.
|
Locked | Locked | Locked |
Investor details for ReproCELL
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ReproCELL
ReproCELL has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include BioServe Biotechnologies, Biopta and Reinnervate.
Investment portfolio details for ReproCELL
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Products and services for stem cell research are supplied.
|
Locked | Locked | 2008 | Locked | |
|
DNA synthesis, sequencing, extraction, and biomarker discovery services are provided.
|
Locked | Locked | 2002 | Locked | |
|
Fresh human tissues are utilized in drug development research.
|
Locked | Locked | 2002 | Locked |
Complete acquisition details for ReproCELL
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ReproCELL
Detailed financials for ReproCELL
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Reprocell Comparisons
Peer comparison for ReproCELL
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ReproCELL
ReproCELL operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of ReproCELL
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Reprocell
Complete news archive for ReproCELL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReproCELL
ReproCELL was founded in 2003 and raised its 1st funding round 3 years after it was founded.
ReproCELL is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
As of Mar 31, 2024, the latest employee count at ReproCELL is 99.
Annual revenue of ReproCELL is $19.94M as on Mar 31, 2025.
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the worlds first human iPS cell products in 2009 and with the worlds most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK) and BioServe (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
ReproCELL's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Yes, ReproCELL is publicly traded on TSE under the ticker symbol 4978.
ReproCELL has made 4 acquisitions, including BioServe Biotechnologies, Biopta, and Reinnervate.
ReproCELL has 2 investors. Key investors include Maryland Stem Cell Research Fund, and SBI Investment.
The ticker symbol of ReproCELL is 4978 on TSE.